Company Overview

Company name: Emerald Bioscience
Description: Emerald Bioscience Inc is a life science biopharmaceutical company. It is engaged in the discovery, development, and the commercialization of cannabinoid-based therapeutics. The company is focused on the development of early-stage cannabinoid product candidates which includes NB1111 for the treatment of glaucoma, and NB2222 for treatment and management of several eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy; and NB3111.
Year founded: 2011
Parent company:
Industry: Healthcare | Group: | Code:
Website: www.emeraldbio.life
Employees: 3
City: Long Beach
State: California
Country: United States
Region:

Financial Highlights

Start up capital raised (USD Million): 3.38
Business status: Profitable
Ownership: Acquired/Merged
Exchange:
Ticker:
Revenue (USD Million): 0.00
Gross profit (USD Million):
Net income (USD Million) 13.48
Enterprise value: 12.30
Earnings before interest, tax, depreciation and amortization (EBITDA): 14.53
Fiscal period: TTM 1Q2020
Financing Status:
Number of active investors:
Profile last updated: 04-Aug-2020
Last known valuation: 1.50
Last known valuation date: 19-Jan-2018